This is one of the main questions buyers have, yet the answer is often presented unclearly. As of September 1, 2026, the federal status of the major kratom alkaloids and related compounds differs significantly.
Mitragynine pseudoindoxyl is currently subject to temporary Schedule I control. The same applies to MGM-15 (dihydro-7-hydroxymitragynine) and MGM-16 (9-fluoro-dihydro-7-hydroxymitragynine). The temporary scheduling period for all three compounds began on August 26, 2026, and is set to remain in effect through August 26, 2028, unless the federal government takes further action.
7-Hydroxymitragynine (7-OH) is in a different position. As of the date above, it is not federally scheduled, although a notice of intent concerning the substance is pending. That notice was published on July 6, 2026.
Mitragynine, the primary alkaloid naturally present in kratom, is also not federally scheduled and was not named in either of the relevant scheduling notices. Likewise, natural leaf kratom that remains below the applicable threshold is not scheduled and was expressly excluded by the DEA.
The DEA filed its notices of intent on July 1, 2026, with publication following on July 6, 2026. The final temporary scheduling order was issued on August 26, 2026, but it applied only to mitragynine pseudoindoxyl, MGM-15, and MGM-16. It did not place 7-OH under Schedule I at that time.
Separately, HHS issued a request for information concerning 7-OH, with the public comment period scheduled to close on September 10, 2026. Because a scheduling order concerning 7-OH may be issued following the applicable federal process, its regulatory status can change quickly.
For that reason, the information above should be treated as accurate as of September 1, 2026, and the latest federal status should always be checked before purchasing, selling, manufacturing, or distributing any kratom-derived product.
